On January 14th, Merck announced on January 12th local time that the US Food and Drug Administration (FDA) has approved Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (CRT) for the treatment of stage III-IVA cervical cancer patients as defined by the International Federation of Obstetrics and Gynecology (FIGO) 2014.